ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup.

A month has gone by since the last earnings report for Icon PLC (ICLR). Shares have lost about 12.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

Investors might want to bet on Icon PLC (ICLR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Icon PLC (ICLR) came out with quarterly earnings of $3.35 per share, missing the Zacks Consensus Estimate of $3.85 per share. This compares to earnings of $3.30 per share a year ago. These figures are ...

SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024, both dates ...

ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board ...

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It ...

ICON PLC (NASDAQ:ICLR) reported its Q3 2025 earnings, surpassing analysts’ expectations with an EPS of $3.31, slightly above the forecast of $3.30. Revenue also exceeded projections, reaching $2.043 ...

DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that it will release its financial results ...

NEW YORK CITY, NY / ACCESS Newswire / April 2, 2025 / Bleichmar Fonti & Auld LLP ("BFA") announces that it has filed a class action lawsuit for violations of the federal securities laws against ICON ...

Dublin, Ireland, 17 April, 2013 – ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, in conjunction with ...

DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and ...